X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ASTRAZENECA PHARMA GLENMARK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 13.1 92.1 14.2% View Chart
P/BV x 2.3 20.3 11.6% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 GLENMARK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-18
GLENMARK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs9301,278 72.8%   
Low Rs517883 58.6%   
Sales per share (Unadj.) Rs322.6228.4 141.2%  
Earnings per share (Unadj.) Rs28.510.4 274.9%  
Cash flow per share (Unadj.) Rs39.216.3 241.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.098.8 185.3%  
Shares outstanding (eoy) m282.1725.00 1,128.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.24.7 47.4%   
Avg P/E ratio x25.4104.2 24.4%  
P/CF ratio (eoy) x18.566.4 27.8%  
Price / Book Value ratio x4.010.9 36.2%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,20627,008 756.1%   
No. of employees `00013.71.4 1,011.5%   
Total wages/salary Rs m18,7181,535 1,219.2%   
Avg. sales/employee Rs Th6,636.84,210.9 157.6%   
Avg. wages/employee Rs Th1,364.71,132.2 120.5%   
Avg. net profit/employee Rs Th586.1191.1 306.7%   
INCOME DATA
Net Sales Rs m91,0315,710 1,594.2%  
Other income Rs m914123 746.1%   
Total revenues Rs m91,9455,833 1,576.4%   
Gross profit Rs m16,154463 3,489.7%  
Depreciation Rs m3,019147 2,048.0%   
Interest Rs m2,8560-   
Profit before tax Rs m11,193438 2,555.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155179 1,763.3%   
Profit after tax Rs m8,039259 3,102.5%  
Gross profit margin %17.78.1 218.9%  
Effective tax rate %28.240.8 69.0%   
Net profit margin %8.84.5 194.6%  
BALANCE SHEET DATA
Current assets Rs m69,8873,209 2,177.7%   
Current liabilities Rs m32,8792,070 1,588.7%   
Net working cap to sales %40.720.0 203.7%  
Current ratio x2.11.6 137.1%  
Inventory Days Days8172 112.6%  
Debtors Days Days9335 267.7%  
Net fixed assets Rs m28,892790 3,655.8%   
Share capital Rs m28250 564.4%   
"Free" reserves Rs m51,3532,419 2,122.6%   
Net worth Rs m51,6352,469 2,091.1%   
Long term debt Rs m41,4180-   
Total assets Rs m125,9544,605 2,734.9%  
Interest coverage x4.9NM-  
Debt to equity ratio x0.80-  
Sales to assets ratio x0.71.2 58.3%   
Return on assets %8.65.6 153.7%  
Return on equity %15.610.5 148.4%  
Return on capital %15.117.7 85.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,317300 12,123.9%   
Fx outflow Rs m9,7202,015 482.4%   
Net fx Rs m26,598-1,715 -1,550.5%   
CASH FLOW
From Operations Rs m16,48188 18,749.1%  
From Investments Rs m-10,133-94 10,826.3%  
From Financial Activity Rs m-4,685NA-  
Net Cashflow Rs m1,770-6 -31,052.6%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 0.3 2,300.0%  
FIIs % 34.4 15.7 219.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   56,727 12,856 441.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 17, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS